filgrastim, Neupogen (cont.)

Medical Author:
Medical and Pharmacy Editor:

DOSING: The recommended dose is 5 to 10 mcg/kg per day. Filgrastim is administered intravenously or subcutaneously (under the skin) for 6 to 14 days. Filgrastim vials should not be shaken since the drug may be damaged, and bubbles may form that can prevent some of the drug from being drawn up into the syringe at the time of injection.

DRUG INTERACTIONS: No clinical studies have been done to determine if filgrastim interacts with other drugs.

PREGNANCY: There are no studies of filgrastim use in pregnant women. Women who become pregnant while receiving filgrastim should enroll in Amgen's Pregnancy Surveillance Program (1-800-772-6436).

NURSING MOTHERS: There are no studies to determine if filgrastim is excreted into breast milk.

SIDE EFFECTS: The most common side effect are nausea, vomiting, bone pain, fever, fatigue, hair loss, and diarrhea. Headache, weight loss, shortness of breath, mouth sores, and rash also occur. Uric acid, lactate dehydrogenase, and alkaline phosphatase levels may rise and spontaneously return to normal levels. Heart attacks and abnormal heart rhythm have been reported.

Reference: FDA Prescribing Information

Last Editorial Review: 11/12/2012

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index